Data / Form D filings / Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC: Form D filings
Deciphera Pharmaceuticals, LLC, a biotechnology company in Waltham, MA, filed 3 Form D notices with the SEC between 2015 and 2017. The latest, on June 5, 2017, reports $52.3 million sold of a $52.3 million offering to 7 investors.
Find out what Deciphera Pharmaceuticals, LLC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 500 Totten Pond Road, 6th Floor, Waltham, MA, 02451
- Phone
- (781) 209-6400
- Industry
- Biotechnology
- Entity type
- Limited Liability Company
- Incorporated in
- Delaware
- Year incorporated
- 2015
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1654151
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 5, 2017 | New notice | $52,299,628 | $52,299,628 | $0 | 7 | May 26, 2017 | sec.gov |
| Jul 14, 2016 | Amendment | $90,604,034 | $90,604,034 | $0 | 5 | Sep 14, 2015 | sec.gov |
| Sep 29, 2015 | New notice | $75,000,000 | $21,551,582 | $53,448,418 | 4 | Sep 14, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael A. Ross | Director | |
| Oliver L. Rosen, M.D. | Executive Officer | |
| Thomas L. Kelly | Executive Officer | |
| Patricia L. Allen | Director | |
| John A. Martin | Director | |
| Daniel L. Flynn, Ph.D. | Executive Officer | |
| Dennis A. Walsh | Director | |
| James A. Bristol, Ph.D. | Director | |
| Christopher J. Morl | Executive Officer | |
| Michael D. Taylor, Ph.D. | Executive Officer, Director | |
| Liam A. Ratcliffe, M.D., Ph.D. | Director | |
| Edward J. Benz, Jr. | Director |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
Every Form D from the week of Jun 5, 2017 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Deciphera Pharmaceuticals, LLC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.